Hims & Hers Stumbles at the Open as Regulatory Damage Hits 2026 Outlook Hard

Core Insights - Hims & Hers Health (HIMS) experienced a 6.6% decline in pre-market trading due to Q1 2026 revenue guidance of $600M-$625M falling short of analyst estimates of $653M, primarily impacted by regulatory changes affecting compounded semaglutide shipping [1] - Despite a strong Q4 2025 performance with revenue growth of 28% to $617.8M and a full-year revenue of $2.35B, the company's Q1 guidance miss overshadowed these results [1] - Regulatory challenges surrounding the compounded semaglutide business have significantly affected Hims & Hers, leading to a nearly 48% drop in stock price over the past month and over 52% year-to-date [1] Financial Performance - Q4 2025 revenue reached $617.8 million, up 28% year-over-year, with earnings per share (EPS) of $0.08 exceeding the consensus estimate of $0.05 [1] - Full-year 2025 revenue was reported at $2.35 billion, reflecting a 59% year-over-year increase, with subscriber numbers surpassing 2.5 million [1] - Q1 2026 revenue guidance of $600 million to $625 million represents a significant shortfall compared to analyst expectations of $653 million, attributed to a $65 million headwind from regulatory changes [1] Regulatory Impact - The regulatory environment has been a critical factor affecting Hims & Hers, particularly the FDA's actions to restrict compounded semaglutide products, which has led to a patent infringement lawsuit from Novo Nordisk [1] - The compounded semaglutide business has faced significant challenges, contributing to a cautious market outlook and a notable decline in stock value [1] - CEO Andrew Dudum emphasized that the majority of revenue and profitability is derived from offerings outside of weight loss, indicating a potential shift in focus for the company [1] Market Outlook - The Q1 guidance miss indicates a real near-term revenue challenge for Hims & Hers, raising concerns about the impact of the semaglutide transition on future performance [1] - Analysts will be monitoring the performance of the Hers brand, which now accounts for nearly 40% of U.S. revenue, and the potential impact of the Eucalyptus acquisition on revenue diversification [1] - Price target revisions by analysts following the earnings report will be a key indicator to watch in the coming days [1]